<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331132</url>
  </required_header>
  <id_info>
    <org_study_id>92/CN-HĐĐĐ</org_study_id>
    <nct_id>NCT04331132</nct_id>
  </id_info>
  <brief_title>Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction</brief_title>
  <acronym>DR-AHF</acronym>
  <official_title>Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gia Dinh People Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Vietnam</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gia Dinh People Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal dysfunction, which comprises 10%-40% of acute heart failure patients (AHF), plays an
      important role in diuretic resistance mechanism. DR-AHF was designed to demonstrate the
      effectiveness of early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in
      acute heart failure patients with renal dysfunction and clinical evidence of loop diuretic
      resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, randomized controlled trial, which will enroll 128
      patients hospitalized due to AHF. These patients with wet-warm phenotype whose estimated
      glomerular filtration rates at admission are above 15 and below 60 mL/min/1.73 m2, and
      cumulative urine output &lt;300 mL in 2 hours after the first dose of intravenous furosemide
      will be randomly assigned 1:1 to receive a standard care with uptitrating intravenous
      furosemide alone or a combination therapy with tolvaptan 15mg once daily for 2 days. The
      standard furosemide treatment will follow the modified 2019 Position Statement from the ESC
      Heart Failure Association. The primary endpoint is the cumulative urine output at 48 hour.
      Key secondary endpoints include the improvement of fractional excretion of sodium at 6 hour,
      the total dose of furosemide, the changes in the body weights, the net fluid loss, the
      lessening of diastolic dysfunction parameters on echocardiography, and the incidence of
      clinically relevant worsening renal function at 48 hour.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Acute heart failure patients with wet-warm phenotype whose estimated glomerular filtration rates at admission are above 15 and below 60 mL/min/1.73 m2, and cumulative urine output &lt;300 mL in 2 hours after the first dose of intravenous furosemide will be randomly assigned 1:1 to receive a standard care with uptitrating intravenous furosemide alone or a combination therapy with tolvaptan 15mg once daily for 2 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative urine volume output at 48h after randomization</measure>
    <time_frame>Hour 48</time_frame>
    <description>Urine volume in mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of furosemide at 48h after randomization</measure>
    <time_frame>Hour 48</time_frame>
    <description>Furosemide dose in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom of dyspnea by 7-point Likert scale at 24h and 48h after randomization</measure>
    <time_frame>Hour 24, Hour 48</time_frame>
    <description>3: markedly better, 2: moderately better, 1: minimally better, 0: no change, -1: minimally worse, -2: moderately worse, -3: markedly worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight at 24h and 48h after randomization</measure>
    <time_frame>Hour 24, Hour 48</time_frame>
    <description>weight in gram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically relevant worsening renal function at 24h and 48h after randomization</measure>
    <time_frame>Hour 24, Hour 48</time_frame>
    <description>An increase in serum creatinine ≥ 0.3 mg/dL within 48 hours accompanying doubling the dose of furosemide according to the diuretic treatment protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum electrolytes measured at 12h, 24h and 48h after randomization</measure>
    <time_frame>Hour 12, Hour 24, Hour 48</time_frame>
    <description>Changes in serum sodium (mmol/L), potassium (mmol/L), chloride (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urine electrolyte excretion at 6h, 24h and 48h</measure>
    <time_frame>Hour 6, Hour 24, Hour 48</time_frame>
    <description>Increase in sodium (mmol/L), potassium (mmol/L) and chloride (mmol/L) excretion adjusted for urine creatinine (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NT-proBNP at 48h after randomization</measure>
    <time_frame>Hour 0, Hour 48</time_frame>
    <description>Changes in NT-proBNP (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mitral e' on echocardiography</measure>
    <time_frame>Hour 24, Hour 48</time_frame>
    <description>Average of septal e' (cm/s) and lateral e' (cm/s) on tissue doppler imaging in apical 4-chamber view</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in E/e' ratio on echocardiography</measure>
    <time_frame>Hour 24, Hour 48</time_frame>
    <description>The ratio between mitral E (cm/s) and average e' (cm/s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left atrial volume on echocardiography</measure>
    <time_frame>Hour 24, Hour 48</time_frame>
    <description>Average of left atrial volumes (ml) by Simpson's rule in apical 4-chamber and 2-chamber view</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tricuspid regurgitation maximal velocity on echocardiography</measure>
    <time_frame>Hour 24, Hour 48</time_frame>
    <description>Tricuspid regurgitation maximal velocity (m/s) by continuous wave doppler in apical 4-chamber view</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inferior vena cava maximal diameter on echocardiography</measure>
    <time_frame>Hour 24, Hour 48</time_frame>
    <description>Inferior vena cava maximal diameter (mm) in subcostal view</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Conventional diuretic group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The conventional furosemide treatment will follow the modified 2019 Position Statement from the ESC Heart Failure Association</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasopressin-2 antagonist group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tolvaptan 15mg once daily for 2 days will be added-on the furosemide strategy based on the modified 2019 Position Statement from the ESC Heart Failure Association</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan 15 MG</intervention_name>
    <description>vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy</description>
    <arm_group_label>Conventional diuretic group</arm_group_label>
    <arm_group_label>Vasopressin-2 antagonist group</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to hospital with a primary diagnosis of acute heart failure with wet-warm
             phenotype

          -  Cumulative urine volume output &lt; 300ml within 2 hours after the first dose of
             intravenous furosemide

          -  eGFR at admission 15-60ml/min/1.73m2

        Exclusion Criteria:

          -  Acute coronary syndrome

          -  Anuria

          -  Sepsis

          -  Consciousness impairment

          -  Pregnant or breastfeeding women

          -  Severe valvular heart diseases (severe valvular stenosis or regurgitation)

          -  Admission sodium level &gt; 140 mEq/L

          -  Serum total bilirubin &gt; 3 mg/dL

          -  Serum potassium &gt; 5.5 mmol/L

          -  Allergy or contraindication for tolvaptan

          -  Emergency indication for hemodialysis

          -  Cardiogenic shock or mechanical circulation support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hai H. Nguyen, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nhat M. Giang, M.D</last_name>
    <phone>+84919963999</phone>
    <email>minhnhat_210189@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hai H. Nguyen, Ph.D</last_name>
    <phone>+84908247359</phone>
    <email>bsnguyenhoanghai@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Department</name>
      <address>
        <city>Ho Chi Minh City</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <contact>
      <last_name>Hai H Nguyen, Ph.D</last_name>
      <phone>+84908247359</phone>
      <email>bsnguyenhoanghai@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nhat M Giang, M.D</last_name>
      <phone>+84919963999</phone>
      <email>minhnhat_210189@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anh H Nguyen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thao T Nguyen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tin T Huynh, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hoa K Tran, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matsue Yuya, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2016 Dec 30;:.</citation>
    <PMID>27206819</PMID>
  </reference>
  <reference>
    <citation>Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 17;75(10):1178-1195. doi: 10.1016/j.jacc.2019.12.059. Review.</citation>
    <PMID>32164892</PMID>
  </reference>
  <reference>
    <citation>Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Feb;21(2):137-155. doi: 10.1002/ejhf.1369. Epub 2019 Jan 1. Review.</citation>
    <PMID>30600580</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute heart failure</keyword>
  <keyword>worsening renal function</keyword>
  <keyword>loop diuretic resistance</keyword>
  <keyword>vasopressin-2 receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

